1Terasaki Hiroshi, Niki Toshiro, Matsuno Yoshihiro, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol, 2003, 27: 937-951.
2Mitsudomi T, Hamajima N, Ogawa M,et al. Prognostic significance of p53 alterations in patients with non-small-cell lung cancer: a meta-analysis. Clin Cancer Res, 2000,6:4055-4063.
3Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. Cell Physiol, 2000,182: 3tl-322.
8Kawachi R, Nakazato Y, Takei H, et al. Clinical significance of preoperative earcinoembryonic antigen level for clinical stage 1 non small cell lung cancer: can preoperative carcinoembryonic an- tigen level predict pathological stage? [-J]. Interact Cardiovasc Thorac Surg,2O09,9(2) : 199-202.
9Koga H,Eguchi K,Shinkai T, et al. Preliminary evaluation of the new tumor markers, CYFRA21-1 ,in lung cancer patients[J]. Jpn J Clin Onco1,1994, 24(5):263-268.
10Pinson P, Joos G, Watdpint P,et al. Serum neuron-specific eno- lase as a tumor markers in the diagnosis and follow-up of small- cell lung cancerl-J]. Respiration, 1997,64 ( 1 ) : 102- 107.
